お知らせ :東京証券取引所JASDAQスタンダード市場への新規上場に関するお知らせ
株式会社グローバルインフォメーション
表紙:慢性閉塞性肺疾患(COPD)治療薬の世界市場:2019年~2023年
市場調査レポート
商品コード
364923

慢性閉塞性肺疾患(COPD)治療薬の世界市場:2019年~2023年

Global Chronic Obstructive Pulmonary Disease (COPD) Drugs Market 2019-2023

出版日: | 発行: TechNavio (Infiniti Research Ltd.) | ページ情報: 英文 118 Pages | 納期: 即納可能 即納可能とは

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=109.20円
慢性閉塞性肺疾患(COPD)治療薬の世界市場:2019年~2023年
出版日: 2019年01月18日
発行: TechNavio (Infiniti Research Ltd.)
ページ情報: 英文 118 Pages
納期: 即納可能 即納可能とは
  • 全表示
  • 概要
  • 目次
概要

COPDは、医学的介入がないと進行し続ける、慢性の非伝染性の生活習慣病です。喫煙、バイオマス燃料への曝露、大気汚染など、ライフスタイルに関連したいくつかの要因があり、これらがCOPDを発症するリスクを高めています。タバコの煙に加えて、職業的曝露、屋外汚染、受動喫煙、バイオマスの燃焼による煙、呼吸器感染症、栄養状態の悪さ、慢性喘息、肺の成長障害、社会経済的状態の悪さ、食事要因などの他の要因があり、これらは直接的または間接的にCOPDを引き起こします。ライフスタイル要因とは別に、老齢やまれな遺伝性疾患の存在などの要因があり、COPDの罹患率の上昇の一因となっています。 Technavioのアナリストは、世界の慢性閉塞性肺疾患(COPD)治療薬市場が2023年までに約4%のCAGRで成長すると予測しています。

当レポートでは、世界の慢性閉塞性肺疾患(COPD)治療薬市場について調査分析し、市場規模と成長率、市場動向、市場促進要因・課題、市場機会について検証するほか、主要ベンダーなどについて、体系的な情報を提供しています。

目次

第1章 エグゼクティブサマリー

第2章 レポートの範囲

  • イントロダクション1
  • イントロダクション2
  • 米ドルの通貨換算レート

第3章 市場状況

  • 市場のエコシステム
  • 市場の特徴
  • 市場セグメンテーション分析

第4章 パイプライン分析

第5章 市場規模

  • 市場の定義
  • 市場規模(2018年)
  • 市場規模および予測(2018年~2023年)

第6章 ファイブフォース分析

  • バイヤーの交渉力
  • サプライヤーの交渉力
  • 新規参入の脅威
  • 代替品の脅威
  • 競争相手の脅威
  • 市況

第7章 市場セグメンテーション:製品別

  • 市場セグメンテーション:製品別
  • 製品別比較:市場規模および予測(2018年~2023年)
  • 併用療法
  • 単剤療法
  • 市場機会:製品別

第8章 顧客情勢

第9章 市場セグメンテーション:タイプ別

  • 慢性気管支炎
  • 肺気腫

第10章 地域情勢

  • 地域別セグメンテーション
  • 地域別比較:市場規模および予測(2018年~2023年)
  • 北米
  • 欧州
  • アジア
  • その他の地域
  • 主要国
  • 市場機会

第11章 成長要因と課題

  • 市場成長要因
  • 市場の課題

第12章 市場トレンド

第13章 ベンダー情勢

  • 概要
  • 創造的破壊の状況

第14章 ベンダー分析

  • 対象ベンダー
  • ベンダー分類
  • ベンダーの市場ポジショニング
  • AstraZeneca
  • Boehringer Ingelheim
  • GlaxoSmithKline
  • Novartis
  • Teva Pharmaceutical

第15章 付録

  • 調査方法
  • 略語のリスト
目次
Product Code: IRTNTR30709

About this market

COPD is a chronic non-communicable, lifestyle-related disease, which progresses continuously in the absence of medical intervention. There are several lifestyle-related factors such as smoking, exposure to biomass fuel, and air pollution, which increase the risk of developing COPD. In addition to tobacco smoke, there are other factors such as occupational exposure, outdoor pollution. exposure to second-hand or passive smoking. smoke from the burning of biomass, respiratory infections, poor nutritional status, chronic asthma, impaired lung growth, poor socio-economic status. and dietary factors, which lead directly or indirectly to COPD. Apart from lifestyle factors, there are factors such as old age and presence of rare genetic disorders. which contribute to the rising prevalence of COPD. Technavio's analysts have predicted that the chronic obstructive pulmonary disease (COPD) drugs market will register a CAGR of almost 4% by 2023.

Market Overview

Strong pipeline and new drug approvals

The pipeline for the treatment of COPD includes several drug combinations, which can provide a wide range of therapeutic benefits. These drug combinations are presently in the late stages of development, with some expected to be launched in the market during the forecast period. These molecules combine the properties of drugs from different classes and have diversified therapeutic mechanisms of action and hence are expected to change the course of COPD treatment.

Low diagnosis rates for COPD

There is a lack of knowledge and awareness about COPD especially in the developing countries due to which primary care practitioners (PCPs) and other healthcare providers delay or incorrectly diagnose COPD. Another major factor contributing to the poor diagnosis of COPD is the diagnostic confusion between COPD and asthma. Thus, poor or incorrect diagnosis is a major challenge as it prevents people with COPD from getting a proper diagnosis which, in turn, has a negative impact on market growth.

For the detailed list of factors that will drive and challenge the growth of the chronic obstructive pulmonary disease (COPD) drugs market during the 2019-2023, view our report.

Competitive Landscape

The chronic obstructive pulmonary disease (COPD) drugs market appears to be moderately concentrated and with the presence of few companies. This market research report will help clients identify new growth opportunities and design unique growth strategies by providing a comprehensive analysis of the market's competitive landscape and offering information on the products offered by companies.

TABLE OF CONTENTS

PART 01: EXECUTIVE SUMMARY

PART 02: SCOPE OF THE REPORT

  • 2.1 Preface
  • 2.2 Preface
  • 2.3 Currency conversion rates for US$

PART 03: MARKET LANDSCAPE

  • Market ecosystem
  • Market characteristics
  • Market segmentation analysis

PART 04: PIPELINE ANALYSIS

PART 05: MARKET SIZING

  • Market definition
  • Market sizing 2018
  • Market size and forecast 2018-2023

PART 06: FIVE FORCES ANALYSIS

  • Bargaining power of buyers
  • Bargaining power of suppliers
  • Threat of new entrants
  • Threat of substitutes
  • Threat of rivalry
  • Market condition

PART 07: MARKET SEGMENTATION BY PRODUCT

  • Market segmentation by product
  • Comparison by product
  • Combination therapy - Market size and forecast 2018-2023
  • Monotherapy - Market size and forecast 2018-2023
  • Market opportunity by product

PART 08: CUSTOMER LANDSCAPE

PART 09: MARKET SEGMENTATION BY TYPE

  • Chronic bronchitis
  • Emphysema

PART 10: GEOGRAPHIC LANDSCAPE

  • Geographic segmentation
  • Geographic comparison
  • North America - Market size and forecast 2018-2023
  • Europe - Market size and forecast 2018-2023
  • Asia - Market size and forecast 2018-2023
  • ROW - Market size and forecast 2018-2023
  • Key leading countries
  • Market opportunity

PART 11: DRIVERS AND CHALLENGES

  • Market drivers
  • Market challenges

PART 12: MARKET TRENDS

PART 13: VENDOR LANDSCAPE

  • Overview
  • Landscape disruption

PART 14: VENDOR ANALYSIS

  • Vendors covered
  • Vendor classification
  • Market positioning of vendors
  • AstraZeneca
  • Boehringer Ingelheim
  • GlaxoSmithKline
  • Novartis
  • Teva Pharmaceutical

PART 15: APPENDIX

  • Research methodology
  • List of abbreviations

List of Exhibits

  • Exhibit 01: Years in consideration
  • Exhibit 02: Global respiratory disorder drugs market
  • Exhibit 03: Segments of global respiratory disorder drugs market
  • Exhibit 04: Market characteristics
  • Exhibit 05: Market segments
  • Exhibit 06: Pipeline molecules for COPD
  • Exhibit 07: Market definition - Inclusions and exclusions checklist
  • Exhibit 08: Market size 2018
  • Exhibit 09: Global market: Size and forecast 2018-2023 ($ millions)
  • Exhibit 10: Global market: Year-over-year growth 2019-2023 (%)
  • Exhibit 11: Five forces analysis 2018
  • Exhibit 12: Five forces analysis 2023
  • Exhibit 13: Bargaining power of buyers
  • Exhibit 14: Bargaining power of suppliers
  • Exhibit 15: Threat of new entrants
  • Exhibit 16: Threat of substitutes
  • Exhibit 17: Threat of rivalry
  • Exhibit 18: Market condition - Five forces 2018
  • Exhibit 19: Product - Market share 2018-2023 (%)
  • Exhibit 20: Comparison by product
  • Exhibit 21: Combination therapy - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 22: Combination therapy - Year-over-year growth 2019-2023 (%)
  • Exhibit 23: Monotherapy - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 24: Monotherapy - Year-over-year growth 2019-2023 (%)
  • Exhibit 25: Sales of monotherapy drugs 2015-2017 ($ millions)
  • Exhibit 26: Market opportunity by product
  • Exhibit 27: Customer landscape
  • Exhibit 28: Market share by geography 2018-2023 (%)
  • Exhibit 29: Geographic comparison
  • Exhibit 30: North America - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 31: North America - Year-over-year growth 2019-2023 (%)
  • Exhibit 32: Europe - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 33: Europe - Year-over-year growth 2019-2023 (%)
  • Exhibit 34: Asia - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 35: Asia - Year-over-year growth 2019-2023 (%)
  • Exhibit 36: ROW - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 37: ROW - Year-over-year growth 2019-2023 (%)
  • Exhibit 38: Key leading countries
  • Exhibit 39: Market opportunity
  • Exhibit 40: Decision framework
  • Exhibit 41: Mechanism of action of budesonide/ glycopyrronium/formoterol triple combination
  • Exhibit 42: New drug approvals for COPD
  • Exhibit 43: US FDA-approved fixed-dose combination LABAs and LAMAs
  • Exhibit 44: Impact of drivers and challenges
  • Exhibit 45: Examples of advanced nebulizers
  • Exhibit 46: Vendor landscape
  • Exhibit 47: Landscape disruption
  • Exhibit 48: Vendors covered
  • Exhibit 49: Vendor classification
  • Exhibit 50: Market positioning of vendors
  • Exhibit 51: AstraZeneca - Vendor overview
  • Exhibit 52: AstraZeneca - Business segments
  • Exhibit 53: AstraZeneca - Organizational developments
  • Exhibit 54: AstraZeneca - Geographic focus
  • Exhibit 55: AstraZeneca - Key offerings
  • Exhibit 56: Boehringer Ingelheim - Vendor overview
  • Exhibit 57: Boehringer Ingelheim - Business segments
  • Exhibit 58: Boehringer Ingelheim - Organizational developments
  • Exhibit 59: Boehringer Ingelheim - Geographic focus
  • Exhibit 60: Boehringer Ingelheim - Segment focus
  • Exhibit 61: Boehringer Ingelheim - Key offerings
  • Exhibit 62: GlaxoSmithKline - Vendor overview
  • Exhibit 63: GlaxoSmithKline - Business segments
  • Exhibit 64: GlaxoSmithKline - Organizational developments
  • Exhibit 65: GlaxoSmithKline - Geographic focus
  • Exhibit 66: GlaxoSmithKline - Segment focus
  • Exhibit 67: GlaxoSmithKline - Key offerings
  • Exhibit 68: Novartis - Vendor overview
  • Exhibit 69: Novartis - Business segments
  • Exhibit 70: Novartis - Organizational developments
  • Exhibit 71: Novartis - Geographic focus
  • Exhibit 72: Novartis - Segment focus
  • Exhibit 73: Novartis - Key offerings
  • Exhibit 74: Teva Pharmaceutical - Vendor overview
  • Exhibit 75: Teva Pharmaceutical - Business segments
  • Exhibit 76: Teva Pharmaceutical - Organizational developments
  • Exhibit 77: Teva Pharmaceutical - Geographic focus
  • Exhibit 78: Teva Pharmaceutical - Segment focus
  • Exhibit 79: Teva Pharmaceutical - Key offerings
  • Exhibit 80: Validation techniques employed for market sizing
  • Exhibit 81: List of abbreviations
株式会社グローバルインフォメーション
© Copyright 1996-2021, Global Information, Inc. All rights reserved.